FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md

@@ -0,0 +1 @@
+<br>The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind, placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US,  Read more such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 trial in the US by end of year. PepGen did not mention a specific reason for the decision